ArticleNeuropsychiatric disease and treatment2009
Review of teriflunomide and its potential in the treatment of multiple sclerosis.
Article in Neuropsychiatric disease and treatment, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2012Trial
- Acute Ischemic Stroke in a Patient with Multiple Sclerosis after Initiating Teriflunomide Treatment: A Challenging Case.Current therapeutic research, clinical and experimental · 2024Article
- Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress.International journal of molecular sciences · 2022Article
- Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations.Therapeutic advances in chronic disease · 2020Article
- Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models.Brain, behavior, and immunity · 2017Article
- Induction of gut regulatory CD39Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications.Frontiers in molecular neuroscience · 2016Review
- [Immunotherapies for multiple sclerosis : review and update].Der Internist · 2015Review
- Neurobehavioral burden of multiple sclerosis with nanotheranostics.Neuropsychiatric disease and treatment · 2015Review
- Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis.Mediators of inflammation · 2015Review
- Iron chelation and multiple sclerosis.ASN neuro · 2014Review
- Multiple sclerosis: overview of disease-modifying agents.Perspectives in medicinal chemistry · 2014Article
- Article
- Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Journal of neural transmission (Vienna, Austria : 1996) · 2013Review
- Teriflunomide in relapsing multiple sclerosis: therapeutic utility.Therapeutic advances in chronic disease · 2013Article
- [Teriflunomide for treatment of multiple sclerosis].Der Nervenarzt · 2013Review
- Teriflunomide.Hospital pharmacy · 2013Article
- Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod.Therapeutics and clinical risk management · 2013Article
- Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action.Biologics : targets & therapy · 2013Review
- Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Neuropsychiatric disease and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.
Indexed as
Identifiers
19557143PMC2699658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.